What is the difference between somatic and germline testing?

Somatic testing evaluates alterations present in tumor or other body cells and not necessarily inherited. Germline testing evaluates inherited variants that are present from conception and may be passed to offspring.

Which polymerase is suitable for low-frequency mutation detection?

A suitable polymerase should combine high fidelity, efficient low-input amplification, low nonspecific activity, and compatibility with the selected primers, probes, molecular barcodes, or sequencing workflow. The best enzyme must be evaluated in the complete assay.

Why does FFPE testing require specialized enzymes?

FFPE-derived DNA and RNA are often fragmented and chemically damaged. Polymerases, reverse transcriptases, repair enzymes, and library preparation enzymes may therefore need to perform efficiently with short or compromised templates.

Which enzymes are needed for fusion detection?

RNA fusion assays commonly use reverse transcriptase followed by a DNA polymerase for targeted amplification or library preparation. DNA ligase, end-processing enzymes, and capture-related enzymes may also be required in NGS workflows.

Can UDG be used for both contamination control and FFPE repair?

Yes, but these are different applications. In PCR contamination control, UDG removes uracil-containing products generated with dUTP. In selected FFPE workflows, UDG may remove uracil resulting from cytosine deamination. Reaction design and enzyme inactivation requirements differ.

Are the same enzymes used for germline and tumor panels?

Some enzyme classes are shared, but performance priorities differ. Germline panels often emphasize uniform coverage and heterozygous variant balance, while tumor panels may require stronger low-frequency variant sensitivity and damaged-template tolerance.

Can you provide enzymes for methylation assays?

Yes. Available options may include methylation-sensitive restriction enzymes, DNA-modifying enzymes, polymerases, ligases, and customized enzyme systems for selected epigenetic workflows.

Can an oncology enzyme be supplied in a lyophilized format?

Availability depends on the enzyme and assay system. Glycerol-free and lyophilization-ready formulations can be evaluated.

Oncology and Genetic Testing Enzymes

Catalog	Product Name	EC No.	CAS No.	Source	Price
BDE-026	Native α-L-fucosidase (AFU) from Microorganism	EC 3.2.1.51		Microorganism	Inquiry
DIA-429	Alpha-L-Fucosidase from Microorganism	EC 3.2.1.51		Microorganism	Inquiry
DIA-499	High Purity Alpha-Fucosidase		9037-65-4	Thermotoga maritima	Inquiry
DIA-586	T4 Polynucleotide Kinase			Escherichia coli	Inquiry
DIA-885	Tissue Alpha-L-Fucosidase (FUCA1)	EC 3.2.1.51	32-1-5150		Inquiry
DIA-906	α-L-Fucosidase	EC 3.2.1.51	9037-65-4		Inquiry
POL-016	Terminal Deoxynucleotidyl Transferase				Inquiry
TRA-061	T4 Polynucleotide Kinase			E.coli	Inquiry

Oncology and genetic testing encompass distinct but connected analytical questions. Tumor profiling examines acquired, or somatic, alterations in cancer cells, while hereditary testing evaluates germline variants that may be passed between generations. Tumor testing may occasionally identify a potentially inherited alteration, but it does not replace dedicated germline testing and appropriate interpretation.

Modern assays may evaluate single-nucleotide variants, insertions and deletions, copy-number changes, gene fusions, splice variants, microsatellite instability, tumor mutational burden, or selected epigenetic features. No single enzyme or assay format is optimal for every variant class.

Creative Enzymes supplies high-fidelity polymerases, hot-start polymerases, reverse transcriptases, ligases, transposases, nucleases, DNA repair enzymes, methylation-sensitive enzymes, and NGS library preparation enzymes for oncology and genetic assay development.

Oncology and genetic testing enzymes

Start with the Analytical Question

Enzyme selection should begin with the biological question the assay must answer.

Q1: Is the Variant Somatic or Germline?

Somatic oncology assays commonly analyze tumor tissue or circulating tumor DNA to identify alterations acquired during tumor development. Germline assays generally analyze non-tumor specimens such as blood, saliva, or buccal cells to identify inherited variants associated with disease susceptibility. Some tumor-normal workflows compare tumor material with matched blood or saliva to help distinguish somatic from potential germline findings.

Q2: Is the Assay Targeted or Broad?

A targeted PCR or digital PCR assay may be appropriate when the relevant hotspot or small set of variants is already known. Broader NGS panels can evaluate multiple genes and variant classes in parallel.

FDA-authorized tumor profiling assays illustrate the use of targeted NGS to detect combinations of substitutions, indels, copy-number changes, fusions, splice variants, microsatellite instability, and tumor mutational burden, depending on the assay design.

Q3: Is the Starting Material DNA or RNA?

DNA-based assays are commonly used for substitutions, indels, copy-number changes, and selected genomic signatures. RNA-based analysis can be particularly valuable for expressed gene fusions, exon-skipping events, splice variants, and transcript-level biomarkers.

RNA workflows require reverse transcription before amplification or library preparation, making reverse transcriptase performance a critical part of assay sensitivity and transcript representation.

Enzyme Selection by Variant Type

Analytical Objective	Representative Enzymes	Important Performance Priorities
Known hotspot mutation detection	Hot-start DNA polymerase, high-fidelity polymerase, UDG/UNG where applicable	Allele discrimination, low background, inhibitor tolerance
Low-frequency somatic variant detection	High-fidelity polymerase, proofreading polymerase, ligase	Low error rate, efficient low-input amplification, minimal bias
Germline panel testing	High-fidelity polymerase, ligase, end-repair and A-tailing enzymes	Uniform coverage, reproducibility, balanced GC performance
Gene fusion and splice-variant detection	Reverse transcriptase, DNA polymerase, ligase	Structured RNA performance, transcript coverage, low template input
Copy-number analysis	High-fidelity polymerase, ligase, transposase	Library uniformity, low amplification bias, consistent coverage
NGS library preparation	End-repair enzymes, A-tailing enzymes, DNA ligase, transposase, polymerase	Library complexity, adapter ligation efficiency, fragment uniformity
FFPE tumor analysis	Proteinase K, DNA repair enzymes, UDG-related enzymes, polymerase	Damaged-template tolerance, artifact control, short-fragment performance
Liquid biopsy and ctDNA testing	High-fidelity polymerase, ligase, end-repair enzymes	Low-input recovery, low error background, molecular-barcode compatibility
Methylation analysis	Methylation-sensitive restriction enzymes, DNA-modifying enzymes, polymerase	Methylation-state selectivity, complete conversion or digestion
Sanger confirmation	Thermostable DNA polymerase, exonuclease, phosphatase	Specific amplification and clean sequencing template preparation

Key Oncology and Genetic Testing Areas

Tumor Tissue and FFPE Testing

Formalin-fixed, paraffin-embedded tissue is widely used for molecular tumor profiling because it is routinely available from pathology workflows. However, fixation and storage can produce fragmented nucleic acids and chemical damage, creating challenges for amplification and library preparation.

Liquid Biopsy and Low-Frequency Variant Detection

Liquid biopsy assays may analyze cell-free DNA or RNA from plasma and other body fluids. In cancer, circulating tumor DNA usually represents only a fraction of total cell-free DNA, and the amount available for detection can vary with tumor biology, disease stage, treatment, and DNA shedding.

Hereditary and Germline Genetic Testing

Hereditary testing evaluates variants that may contribute to inherited cancer susceptibility or other genetic conditions. Testing may use targeted genotyping, Sanger sequencing, deletion or duplication analysis, multigene panels, exome sequencing, or genome sequencing. NCI distinguishes inherited cancer testing from tumor biomarker testing and notes that germline testing commonly uses blood, saliva, buccal cells, or other non-tumor specimens.

Fusion, Splice, and RNA Biomarker Testing

Some clinically relevant alterations are more readily detected at the RNA level because the resulting transcript directly joins fusion partners or reveals abnormal exon usage. Reverse transcription can be followed by targeted PCR, digital PCR, amplicon sequencing, hybrid-capture sequencing, or other transcript analysis methods.

NGS Library Preparation Enzymes

NGS library preparation converts DNA or cDNA into sequencing-compatible fragments with the required adapters and indexing sequences. Related enzymes include end repair and A-tailing Enzymes, DNA ligases, transposases, high-fidelity polymerases, and reverse transcriptases.

Why Choose Creative Enzymes?

Molecular enzymes covering targeted PCR, dPCR, Sanger, and NGS workflows
Products for DNA, RNA, FFPE, liquid biopsy, and germline applications
Support for mutation, fusion, copy-number, methylation, and library preparation assays
Native, recombinant, liquid, glycerol-free, and lyophilized formats
Application-specific enzyme engineering and formulation
Flexible supply for feasibility, verification, and production needs

FAQs

Q1. What is the difference between somatic and germline testing?

A1. Somatic testing evaluates alterations present in tumor or other body cells and not necessarily inherited. Germline testing evaluates inherited variants that are present from conception and may be passed to offspring.
Q2. Which polymerase is suitable for low-frequency mutation detection?

A2. A suitable polymerase should combine high fidelity, efficient low-input amplification, low nonspecific activity, and compatibility with the selected primers, probes, molecular barcodes, or sequencing workflow. The best enzyme must be evaluated in the complete assay.
Q3. Why does FFPE testing require specialized enzymes?

A3. FFPE-derived DNA and RNA are often fragmented and chemically damaged. Polymerases, reverse transcriptases, repair enzymes, and library preparation enzymes may therefore need to perform efficiently with short or compromised templates.
Q4. Which enzymes are needed for fusion detection?

A4. RNA fusion assays commonly use reverse transcriptase followed by a DNA polymerase for targeted amplification or library preparation. DNA ligase, end-processing enzymes, and capture-related enzymes may also be required in NGS workflows.
Q5. Can UDG be used for both contamination control and FFPE repair?

A5. Yes, but these are different applications. In PCR contamination control, UDG removes uracil-containing products generated with dUTP. In selected FFPE workflows, UDG may remove uracil resulting from cytosine deamination. Reaction design and enzyme inactivation requirements differ.
Q6. Are the same enzymes used for germline and tumor panels?

A6. Some enzyme classes are shared, but performance priorities differ. Germline panels often emphasize uniform coverage and heterozygous variant balance, while tumor panels may require stronger low-frequency variant sensitivity and damaged-template tolerance.
Q7. Can you provide enzymes for methylation assays?

A7. Yes. Available options may include methylation-sensitive restriction enzymes, DNA-modifying enzymes, polymerases, ligases, and customized enzyme systems for selected epigenetic workflows.
Q8. Can an oncology enzyme be supplied in a lyophilized format?

A8. Availability depends on the enzyme and assay system. Glycerol-free and lyophilization-ready formulations can be evaluated.